Juvenile recurrent respiratory papillomatosis treated with combined erlotinib and celecoxib: Initial report.
Int J Pediatr Otorhinolaryngol
; 137: 110194, 2020 Oct.
Article
em En
| MEDLINE
| ID: mdl-32658799
ABSTRACT
Recurrent respiratory papillomatosis (RRP) is a chronic disease caused by human papillomavirus (HPV). RRP is a clinical challenge because of the high recurrence rate, poor surgery response, extension to tracheobronchial tree and because of the risk of malignancy in some cases. There is no consensus on which adjuvant therapy is better for those patients with highly recurrent course. Because papilloma cells overexpress the epidermal growth factor receptor (EGFR), together with an increased expression of COX-2 and prostaglandin E2, the combination of erlotinib and celecoxib seems plausible, and could be proposed for patients with poor response to previous lines of treatment.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Infecções Respiratórias
/
Infecções por Papillomavirus
/
Inibidores de Ciclo-Oxigenase 2
/
Celecoxib
/
Cloridrato de Erlotinib
/
Antineoplásicos
Limite:
Adolescent
/
Adult
/
Child
/
Child, preschool
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article